Cristina Marco
Family · Mission Hills, CANPI 1346900081
Payments from drug & device makers
Across 750 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$3K
- Novo Nordisk$2K
- Corcept Therapeutics$2K
- Boehringer Ingelheim$1K
- Lilly USA, LLC$1K
- Abbott$1K
- plus $7K from 32 others
What the payments were for
- Food & beverage$18,034100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 105 | $3,471 |
| Novo Nordisk | 151 | $2,175 |
| Corcept Therapeutics | 44 | $1,512 |
| Boehringer Ingelheim | 61 | $1,422 |
| Lilly USA, LLC | 46 | $1,279 |
| Abbott | 39 | $1,126 |
| Xeris Pharmaceuticals, Inc. | 50 | $1,006 |
| Sanofi-aventis U.S. LLC | 25 | $669 |
| Amgen | 32 | $663 |
| Tandem Diabetes Care, Inc. | 30 | $649 |
| Bayer | 27 | $645 |
| Radius Health, Inc. | 32 | $597 |
| Mannkind Corporation | 9 | $489 |
| Ascendis Pharma Endocrinology Inc | 25 | $405 |
| AstraZeneca(2 entities) | 12 | $305 |
| Medtronic | 6 | $236 |
| Insulet Corporation | 4 | $194 |
| Sequel Med Tech, LLC | 10 | $144 |
| Kyowa Kirin, Inc. | 5 | $129 |
| GSK | 6 | $128 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $125 |
| BETA Bionics, Inc. | 3 | $94 |
| Novartis | 4 | $91 |
| Cequr Corporation | 2 | $69 |
| Antares Pharma, Inc. | 3 | $55 |
| Tolmar, Inc. | 3 | $51 |
| Ascensia Diabetes Care US Inc. | 2 | $48 |
| Amphastar Pharmaceuticals, Inc. | 2 | $39 |
| Ionis Pharmaceuticals, Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Madrigal Pharmaceuticals | 1 | $26 |
| Merck | 1 | $25 |
| Embecta Corp. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| Chiesi USA, Inc. | 1 | $15 |
| Smith+Nephew | 1 | $14 |
| Halozyme Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$1,262
- Korlym$593
- FREESTYLE LIBRE 3$438
- MOUNJARO$368
- JARDIANCE$351
- AFREZZA$250
- Omnipod$150
- FreeStyle Libre 2$144
- TZIELD$141
- MINIMED 780G$138
- RECORLEV$135
- EVENITY$125
- NEFFY$125
- V-GO$125
- Kerendia$109
How this compares
$18,034 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 138 | $227,776 |
| JardianceEmpagliflozin | 104 | $147,357 |
| MounjaroTirzepatide | 91 | $113,880 |
| TrulicityDulaglutide | 36 | $69,277 |
| RybelsusSemaglutide | 29 | $57,474 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $36,552 |
| FarxigaDapagliflozin Propanediol | 23 | $33,018 |
| JanuviaSitagliptin Phosphate | 22 | $29,220 |
| TradjentaLinagliptin | 25 | $21,713 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $20,382 |
| GlyxambiEmpagliflozin/Linagliptin | 14 | $19,279 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $18,018 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $15,119 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $13,668 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $12,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,175 | $285,250167 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $1,422 | $188,349143 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,279 | $183,157127 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $669 | $36,55219 claims |
| AstraZenecaFarxiga | $305 | $33,01823 claims |
| MerckJanuvia | $25 | $29,22022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Mission Hills
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.